0001562180-21-004525.txt : 20210628 0001562180-21-004525.hdr.sgml : 20210628 20210628161852 ACCESSION NUMBER: 0001562180-21-004525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210624 FILED AS OF DATE: 20210628 DATE AS OF CHANGE: 20210628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mills Kenneth T. CENTRAL INDEX KEY: 0001652824 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 211053610 MAIL ADDRESS: STREET 1: C/O REGENXBIO INC. STREET 2: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2021-06-24 false 0001590877 REGENXBIO Inc. RGNX 0001652824 Mills Kenneth T. C/O REGENXBIO INC. 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 true true false false President and CEO Common Stock 2021-06-24 4 M false 4500.00 3.76 A 285484.00 D Common Stock 2021-06-24 4 S false 4500.00 40.02 D 280984.00 D Common Stock 2021-06-25 4 M false 1500.00 3.76 A 282484.00 D Common Stock 2021-06-25 4 S false 1500.00 40.25 D 280984.00 D Employee Stock Option (Right to Buy) 3.76 2021-06-24 4 M false 4500.00 0.00 D 2025-05-18 Common Stock 4500.00 270500.00 D Employee Stock Option (Right to Buy) 3.76 2021-06-25 4 M false 1500.00 0.00 D 2025-05-18 Common Stock 1500.00 269000.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. /s/ Patrick J. Christmas as attorney-in-fact 2021-06-28